Espinoza Octavio's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed May 13, 2025
- Accession no.
- 0002001011-25-000028
- Filed
- May 13, 2025
- Trade date
- May 9, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $156.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Espinoza OctavioCIK 0001905248 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 9, 2025 | Common Stock | PPurchaseAcquired | +1,000 | $103.89 | +$103,890 | 27,432 | Direct | |
| May 9, 2025 | Common Stock | PPurchaseAcquired | +500 | $104.40 | +$52,200 | 27,932 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.